| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marwa El-Hussieny, Mansoura A Abd-El-Maksoud, Fouad M Soliman, Marwa A Fouad, Mohamed K El-Ashre. Dual-target ligand discovery for Alzheimer's disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation. Journal of enzyme inhibition and medicinal chemistry. vol 38. issue 1. 2023-01-25. PMID:36695002. |
dual-target ligand discovery for alzheimer's disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation. |
2023-01-25 |
2023-08-14 |
Not clear |
| Fang Wang, Mingxue Liu, Xiankang Niu, Lian Xia, Fengli Q. Dextran-assisted ultrasonic exfoliation of two-dimensional metal-organic frameworks to evaluate acetylcholinesterase activity and inhibitor screening. Analytica chimica acta. vol 1243. 2023-01-25. PMID:36697184. |
acetylcholinesterase (ache) is regarded as a biomarker of alzheimer's disease (ad), and its inhibitors show great potential in ad therapy as ache can increase the neurotoxicity of the amyloid component that induces ad. |
2023-01-25 |
2023-08-14 |
Not clear |
| María-Ángeles Cortés-Gómez, Víctor M Barberá, Jordi Alom, Javier Sáez-Valero, María-Salud García-Aylló. Presenilin 1 Modulates Acetylcholinesterase Trafficking and Maturation. International journal of molecular sciences. vol 24. issue 2. 2023-01-21. PMID:36674948. |
in alzheimer's disease (ad), the reduction in acetylcholinesterase (ache) enzymatic activity is not paralleled with changes in its protein levels, suggesting the presence of a considerable enzymatically inactive pool in the brain. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ignazio Schino, Mariangela Cantore, Modesto de Candia, Cosimo D Altomare, Catarina Maria, João Barros, Vasco Cachatra, Patrícia Calado, Karina Shimizu, Adilson A Freitas, Maria C Oliveira, Maria J Ferreira, José N C Lopes, Nicola A Colabufo, Amélia P Raute. Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678552. |
alzheimer's disease (ad) is characterized by a progressive cholinergic neurotransmission imbalance, with a decrease of acetylcholinesterase (ache) activity followed by a significant increase of butyrylcholinesterase (bche) in the later ad stages. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ashraf K El-Damasy, Jong Eun Park, Hyun Ji Kim, Jinhyuk Lee, Eun-Kyoung Bang, Hoon Kim, Gyochang Keu. Identification of New Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678580. |
identification of new monoamine oxidase-b (mao-b), acetylcholinesterase (ache), and butyrylcholinesterase (bche) have been considered target enzymes of depression and neurodegenerative diseases, including alzheimer's disease (ad). |
2023-01-21 |
2023-08-14 |
Not clear |
| Raquel B M de Almeida, Deyse B Barbosa, Mayra R do Bomfim, Jéssika A O Amparo, Bruno S Andrade, Silvia L Costa, Joaquín M Campos, Jorddy N Cruz, Cleydson B R Santos, Franco H A Leite, Mariana B Botur. Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678592. |
the enhancement of cholinergic functions via acetylcholinesterase (ache) and butyrylcholinesterase (buche) inhibition is considered a valuable therapeutic strategy for the treatment of alzheimer's disease. |
2023-01-21 |
2023-08-14 |
Not clear |
| Shraddha Manish Gupta, Ashok Behera, Neetesh K Jain, Devendra Kumar, Avanish Tripathi, Shailesh Mani Tripathi, Somdutt Mujwar, Jeevan Patra, Arvind Neg. Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer's: Design, Synthesis, and Biological Evaluation. Pharmaceutics. vol 15. issue 1. 2023-01-21. PMID:36678724. |
indene-derived hydrazides targeting acetylcholinesterase enzyme in alzheimer's: design, synthesis, and biological evaluation. |
2023-01-21 |
2023-08-14 |
Not clear |
| Shraddha Manish Gupta, Ashok Behera, Neetesh K Jain, Devendra Kumar, Avanish Tripathi, Shailesh Mani Tripathi, Somdutt Mujwar, Jeevan Patra, Arvind Neg. Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer's: Design, Synthesis, and Biological Evaluation. Pharmaceutics. vol 15. issue 1. 2023-01-21. PMID:36678724. |
as acetylcholinesterase (ache) plays a crucial role in advancing alzheimer's disease (ad), its inhibition is a promising approach for treating ad. |
2023-01-21 |
2023-08-14 |
Not clear |
| Maram B Alhawarri, Roza Dianita, Mira Syahfriena Amir Rawa, Toshihiko Nogawa, Habibah A Waha. Potential Anti-Cholinesterase Activity of Bioactive Compounds Extracted from Plants (Basel, Switzerland). vol 12. issue 2. 2023-01-21. PMID:36679057. |
potential anti-cholinesterase activity of bioactive compounds extracted from acetylcholinesterase (ache) inhibitors remain the primary therapeutic drug that can alleviate alzheimer's disease's (ad) symptoms. |
2023-01-21 |
2023-08-14 |
Not clear |
| Hazera Khatun Koly, Kakan Sutradhar, Md Sajjadur Rahma. Acetylcholinesterase inhibition of Alzheimer's disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition. Journal of biomolecular structure & dynamics. 2023-01-18. PMID:36651199. |
acetylcholinesterase inhibition of alzheimer's disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition. |
2023-01-18 |
2023-08-14 |
Not clear |
| José María García-Alberca, Esther Gris, Paz de la Guía, Silvia Mendoza, María López de la Ric. Efficacy of Souvenaid® Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2023-01-15. PMID:36641676. |
efficacy of souvenaid® combined with acetylcholinesterase inhibitors in the treatment of mild alzheimer's disease. |
2023-01-15 |
2023-08-14 |
Not clear |
| Martin Valis, Alzbeta Dlabkova, Jakub Hort, Francesco Angelucci, Jaroslav Pejchal, Kamil Kuca, Zbysek Pavelek, Jana Zdarova Karasova, Michal Novotn. The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 159. 2023-01-11. PMID:36630846. |
the acetylcholinesterase inhibitor donepezil is administered as a treatment for alzheimer's disease (ad). |
2023-01-11 |
2023-08-14 |
Not clear |
| Mingjuan Yang, Xinyu Zhang, Ou Qiao, Haixia Ji, Yi Zhang, Xiaoying Han, Wenzhe Wang, Xia Li, Juan Wang, Lanping Guo, Luqi Huang, Wenyuan Ga. Rosmarinic acid potentiates and detoxifies tacrine in combination for Alzheimer's disease. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 109. 2023-01-07. PMID:36610144. |
within the next few decades, acetylcholinesterase inhibitors (acheis) will be the most widely used treatment for alzheimer's disease. |
2023-01-07 |
2023-08-14 |
Not clear |
| Mervat Hassan, Hisham Ismail, Olfat Hammam, Abdullrahman Elsayed, Othman Othman, Sohair Al. Natural inhibitors for acetylcholinesterase and autophagy modulators as effective antagonists for tau and β-amyloid in Alzheimer's rat model. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2023-01-03. PMID:36594248. |
natural inhibitors for acetylcholinesterase and autophagy modulators as effective antagonists for tau and β-amyloid in alzheimer's rat model. |
2023-01-03 |
2023-08-14 |
rat |
| Ilaria Ippoliti, Antonio Ancidoni, Roberto Da Cas, Andrea Pierantozzi, Nicola Vanacore, Francesco Trott. Anti-dementia drugs: a descriptive study of the prescription pattern in Italy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2023-01-03. PMID:36595207. |
acetylcholinesterase inhibitors (acheis) and memantine are currently the only anti-dementia drugs (adds) approved for treating alzheimer's disease (ad) in italy. |
2023-01-03 |
2023-08-14 |
Not clear |
| Aso Hameed Hasan, Sonam Shakya, Faiq H S Hussain, Sankaranarayanan Murugesan, Subhash Chander, Mohammad Rizki Fadhil Pratama, Shajarahtunnur Jamil, Basundhara Das, Subhrajit Biswas, Joazaizulfazli Jamali. Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids. Journal of biomolecular structure & dynamics. 2023-01-02. PMID:36591704. |
acetylcholinesterase inhibitors (acheis) are the most prescribed class of medications for the treatment of alzheimer's disease (ad) and dementia. |
2023-01-02 |
2023-08-14 |
Not clear |
| Ce Zhang, Mingan Li, Wei Xie, Min Li, Chunna You, Tian Wang, Fenghua F. Administration of Huperzine a microspheres ameliorates myocardial ischemic injury via α7nAChR-dependent JAK2/STAT3 signaling pathway. European journal of pharmacology. 2022-12-23. PMID:36563953. |
acetylcholinesterase (ache) inhibitor (achei) is well established as first-line agents for relieving the symptoms of alzheimer's disease (ad). |
2022-12-23 |
2023-08-14 |
mouse |
| Rebecca Lustosa Silva de Almeida Luz, Raquel B M Almeida, Mara Márcia Sampaio Albuquerque, Amanda Ponce Morais Cerqueira, Josean Fechine, Marcelo Sobral da Silva, Raimundo Braz Filho, Manoelito C Dos Santos Junior, Alexsandro Branco, Mariana B Botur. Two new dilactonized glycerol glycosides of the dual anticholinesterase active extract from Ocotea daphnifolia using bioguided fractionation and molecular docking studies. Chemical biology & drug design. 2022-12-17. PMID:36527177. |
the dual inhibition of acetylcholinesterase (ache) and butyrylcholinesterase (buche) is considered as an important strategy for the treatment of alzheimer's disease. |
2022-12-17 |
2023-08-14 |
Not clear |
| b' Simone Lista, Andrea Vergallo, Stefan J Teipel, Pablo Lemercier, Filippo Sean Giorgi, Audrey Gabelle, Francesco Garaci, Nicola B Mercuri, Claudio Babiloni, Bhakta Prasad Gaire, Yosef Koronyo, Maya Koronyo-Hamaoui, Harald Hampel, Robert Nistic\\xc3\\xb. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer\'s disease: relevance for precision medicine in neurodegenerative diseases. Ageing research reviews. 2022-12-16. PMID:36526257.' |
determinants of approved acetylcholinesterase inhibitor response outcomes in alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. |
2022-12-16 |
2023-08-14 |
Not clear |
| b' Simone Lista, Andrea Vergallo, Stefan J Teipel, Pablo Lemercier, Filippo Sean Giorgi, Audrey Gabelle, Francesco Garaci, Nicola B Mercuri, Claudio Babiloni, Bhakta Prasad Gaire, Yosef Koronyo, Maya Koronyo-Hamaoui, Harald Hampel, Robert Nistic\\xc3\\xb. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer\'s disease: relevance for precision medicine in neurodegenerative diseases. Ageing research reviews. 2022-12-16. PMID:36526257.' |
acetylcholinesterase inhibitors (chei) are the global standard of care for the symptomatic treatment of alzheimer's disease (ad) and show significant positive effects in neurodegenerative diseases with cognitive and behavioral symptoms. |
2022-12-16 |
2023-08-14 |
Not clear |